Paper36484006
Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.
Zhao J and 4 others. J Cancer, 2022. Cited by 13 papers, by iCite.
Cite this record
ConductScience Library. Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review. Papers, record 36484006. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36484006
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References69
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22101430 | Natural killer cells act as rheostats modulating antiviral T cells. | Nature | 2011 | https://conductscience.org/library/papers/22101430 | PubMed |
| 2 | 27156385 | Maternal-Derived Hepatitis B Virus e Antigen Alters Macrophage Function in Offspring to Drive Viral Persistence after Vertical Transmission. | Immunity | 2016 | https://conductscience.org/library/papers/27156385 | PubMed |
| 3 | 23775956 | Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23775956 | PubMed |
| 4 | 32278215 | Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients. | Lung Cancer | 2020 | https://conductscience.org/library/papers/32278215 | PubMed |
| 5 | 25642417 | CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. | Front Oncol | 2014 | https://conductscience.org/library/papers/25642417 | PubMed |
| 6 | 32863270 | Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. | J Immunother Cancer | 2020 | https://conductscience.org/library/papers/32863270 | PubMed |
| 7 | 32547550 | Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review. | Front Immunol | 2020 | https://conductscience.org/library/papers/32547550 | PubMed |
| 8 | 26541610 | Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. | Science | 2015 | https://conductscience.org/library/papers/26541610 | PubMed |
| 9 | 30347289 | Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. | Eur J Cancer | 2018 | https://conductscience.org/library/papers/30347289 | PubMed |
| 10 | 26121644 | Doxorubicin Activates Hepatitis B Virus Replication by Elevation of p21 (Waf1/Cip1) and C/EBPα Expression. | PLoS One | 2015 | https://conductscience.org/library/papers/26121644 | PubMed |
| 11 | 29156044 | Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy. | J Infect Dis | 2017 | https://conductscience.org/library/papers/29156044 | PubMed |
| 12 | 28751160 | M4IDP, a zoledronic acid derivative, induces G1 arrest, apoptosis and autophagy in HCT116 colon carcinoma cells via blocking PI3K/Akt/mTOR pathway. | Life Sci | 2017 | https://conductscience.org/library/papers/28751160 | PubMed |
| 13 | 24367534 | Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. | PLoS One | 2013 | https://conductscience.org/library/papers/24367534 | PubMed |
| 14 | 25789969 | T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. | Cell Death Dis | 2015 | https://conductscience.org/library/papers/25789969 | PubMed |
| 15 | 23548749 | PD-1 coinhibitory signals: the link between pathogenesis and protection. | Semin Immunol | 2013 | https://conductscience.org/library/papers/23548749 | PubMed |
| 16 | 25491730 | The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. | Expert Opin Ther Targets | 2015 | https://conductscience.org/library/papers/25491730 | PubMed |
| 17 | 31753012 | Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/31753012 | PubMed |
| 18 | 30565239 | What did we learn from CTLA-4 insufficiency on the human immune system? | Immunol Rev | 2019 | https://conductscience.org/library/papers/30565239 | PubMed |
| 19 | 28434648 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. | Lancet | 2017 | https://conductscience.org/library/papers/28434648 | PubMed |
| 20 | 29406396 | Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. | Melanoma Res | 2018 | https://conductscience.org/library/papers/29406396 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42125666 | Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: the infection- immunity-cancer crosstalk. | Front Immunol | 2026 | https://conductscience.org/library/papers/42125666 | PubMed |
| 41743730 | HBV reactivation during immunotherapy for hepatocellular carcinoma: risk factors and clinical management. | Front Immunol | 2026 | https://conductscience.org/library/papers/41743730 | PubMed |
| 41183666 | Antineoplastic agents-associated hepatitis B virus reactivation: Research progress and molecular mechanisms. | Virus Res | 2025 | https://conductscience.org/library/papers/41183666 | PubMed |
| 40762016 | Neoadjuvant immunotherapy for resectable primary liver cancer (Review). | Oncol Lett | 2025 | https://conductscience.org/library/papers/40762016 | PubMed |
| 40196369 | Efficacy and safety of PD-1/PD-L1 inhibitors combined with tyrosine kinase inhibitors as first-line treatment for hepatocellular carcinoma: a meta-analysis and trial sequential analysis of randomized controlled trials. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40196369 | PubMed |
| 39853863 | Drug-Induced Liver Injury Associated With Emerging Cancer Therapies. | Liver Int | 2025 | https://conductscience.org/library/papers/39853863 | PubMed |
| 39796705 | Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39796705 | PubMed |
| 39717542 | Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies. | Front Cell Infect Microbiol | 2024 | https://conductscience.org/library/papers/39717542 | PubMed |
| 38948476 | Hepatitis-related adverse events associated with immune checkpoint inhibitors in cancer patients: an observational, retrospective, pharmacovigilance study using the FAERS database. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38948476 | PubMed |
| 38721408 | Management of Hepatitis B Virus and Hepatitis C Virus Infections in Patients with Cancer Receiving Immune Checkpoint Inhibitors. | J Immunother Precis Oncol | 2024 | https://conductscience.org/library/papers/38721408 | PubMed |
| 37226111 | Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trials. | BMC Cancer | 2023 | https://conductscience.org/library/papers/37226111 | PubMed |
| 37168999 | The safety concerns regarding immune checkpoint inhibitors in liver cancer patients rising mainly from CHB. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37168999 | PubMed |
Genes11
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| CD274 | 29126 | PubTator's text mining | https://conductscience.org/library/genes/29126 | NCBI Gene |
| CTLA4 | 1493 | PubTator's text mining | https://conductscience.org/library/genes/1493 | NCBI Gene |
| HAVCR2 | 84868 | PubTator's text mining | https://conductscience.org/library/genes/84868 | NCBI Gene |
| LAG3 | 3902 | PubTator's text mining | https://conductscience.org/library/genes/3902 | NCBI Gene |
| MS4A1 | 931 | PubTator's text mining | https://conductscience.org/library/genes/931 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PDCD1 | 5133 | PubTator's text mining | https://conductscience.org/library/genes/5133 | NCBI Gene |
| SLC17A5 | 26503 | PubTator's text mining | https://conductscience.org/library/genes/26503 | NCBI Gene |
| TIGIT | 201633 | PubTator's text mining | https://conductscience.org/library/genes/201633 | NCBI Gene |
| TNFRSF8 | 943 | PubTator's text mining | https://conductscience.org/library/genes/943 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36484006
GET https://conductscience.org/api/papers/v1/36484006/references?page=2